Pharmaceuticals, Biotechnology and Life Sciences
As a part of Clintec’s – a privately-owned full-service Clinical Research Organisation (CRO) – 20th anninversary and reaching certain milestones after another year of growth, Clintec on Wednesday launched its new brand identity reflected in their newly created website.
At least 13 people were killed and 85 injured when a suicide bomber struck Monday evening around 6pm outside the Punjab Assembly in Lahore during a protest, reported Pakistani Dawn citing police officials.
Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
Probi AB has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
Turbulent several months for Teva in which it saw many challenges and achievements saw the company loosing its CEO, several trials in the USA, one of which being for bribery, and patent related trials that Teva filed, and was filed against.
Hutchison China MediTech Limited (Chi-Med) has kicked off today in Australia the first-in-human (FIH) Phase I clinical testing of inhibitor HMPL-453, for fibroblast growth factor receptor signaling pathway, which forces tumor growth.
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
Horizon Discovery Group has sign a Master Services Agreement with its largest customer, which will be a template for increasing revenue for about £2 million in 2017.
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).